CN108473435A - 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 - Google Patents
自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 Download PDFInfo
- Publication number
- CN108473435A CN108473435A CN201680062131.XA CN201680062131A CN108473435A CN 108473435 A CN108473435 A CN 108473435A CN 201680062131 A CN201680062131 A CN 201680062131A CN 108473435 A CN108473435 A CN 108473435A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- salt
- enantiomter
- racemate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(c1cc(*)ccc1*)=*C=I Chemical compound *C(c1cc(*)ccc1*)=*C=I 0.000 description 12
- YAOMFFXQHAOGEC-UHFFFAOYSA-N CN(C)C(C(CC(C1)C2)C3)C1CC23Sc1c(cc(cc2)F)c2ncn1 Chemical compound CN(C)C(C(CC(C1)C2)C3)C1CC23Sc1c(cc(cc2)F)c2ncn1 YAOMFFXQHAOGEC-UHFFFAOYSA-N 0.000 description 1
- CZVHDNTXUQTGRZ-UHFFFAOYSA-N COC(CC(CC(C1)C2)(CC1C1)CC21Sc1c(cc(cc2)F)c2ncn1)=O Chemical compound COC(CC(CC(C1)C2)(CC1C1)CC21Sc1c(cc(cc2)F)c2ncn1)=O CZVHDNTXUQTGRZ-UHFFFAOYSA-N 0.000 description 1
- WGJJZURCPUJWIV-UHFFFAOYSA-N FC(C=C12)=CCC=C1N=CN=C2Cl Chemical compound FC(C=C12)=CCC=C1N=CN=C2Cl WGJJZURCPUJWIV-UHFFFAOYSA-N 0.000 description 1
- WMPSQXLZNFEYEP-UHFFFAOYSA-N Fc(cc12)ccc1ncnc2S Chemical compound Fc(cc12)ccc1ncnc2S WMPSQXLZNFEYEP-UHFFFAOYSA-N 0.000 description 1
- QQZIGZJWWCJXIG-UHFFFAOYSA-N Fc(ccc1ncn2)cc1c2SC(CCC1)CC1c(c1ncn2)cc(F)cc1c2SC1C(CC2)CC2C1 Chemical compound Fc(ccc1ncn2)cc1c2SC(CCC1)CC1c(c1ncn2)cc(F)cc1c2SC1C(CC2)CC2C1 QQZIGZJWWCJXIG-UHFFFAOYSA-N 0.000 description 1
- RKQROBGQKNMESF-UHFFFAOYSA-N Fc(ccc1ncn2)cc1c2SC1(CC(C2)C3)CC3CC2C1 Chemical compound Fc(ccc1ncn2)cc1c2SC1(CC(C2)C3)CC3CC2C1 RKQROBGQKNMESF-UHFFFAOYSA-N 0.000 description 1
- QIMLMMQPGUDWOI-UHFFFAOYSA-N Fc(ccc1ncn2)cc1c2SC1CCCC1 Chemical compound Fc(ccc1ncn2)cc1c2SC1CCCC1 QIMLMMQPGUDWOI-UHFFFAOYSA-N 0.000 description 1
- WCSMZAHKVXOYLH-UHFFFAOYSA-N O=C(c1c2)NC=Nc1ccc2F Chemical compound O=C(c1c2)NC=Nc1ccc2F WCSMZAHKVXOYLH-UHFFFAOYSA-N 0.000 description 1
- MZQYEXKXFXQJMD-UHFFFAOYSA-N Oc1ccc(CCNc2c(cc(cc3)Cl)c3ncn2)cc1 Chemical compound Oc1ccc(CCNc2c(cc(cc3)Cl)c3ncn2)cc1 MZQYEXKXFXQJMD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
本申请公开了作为自噬潮活化剂的化合物和包含所述活化剂的药物组合物。其进一步公开了所述化合物和所述药物组合物在治疗神经变性疾病、特别是蛋白质病和例如阿兹海默氏病的tau病中的用途。其进一步公开了增强自噬潮的方法。
Description
相关申请案
本申请要求2015年10月5日提交的美国临时申请序列号62/237,342的优先权。上述申请的全部内容通过引用并入本文,如同在本文中全部陈述一样。
技术领域
本公开涉及作为自噬潮活化剂的化合物和包含所述化合物的药物组合物。其进一步涉及所述化合物在治疗神经变性疾病、特别是阿兹海默氏病(Alzheimer’s disease)中的用途。
发明背景
阿兹海默氏病(AD)影响约五百万美国人,并且截至2050年,预计这个数字将增加三倍。目前,没有治疗阿尔茨海默氏病或其他相关tau病的疗法。尽管使用靶向淀粉样蛋白β(Aβ)的免疫疗法的临床试验已经取得了有限的成功,但是这仅仅是患有AD或其他神经变性疾病的那些患者的亚组。此外,没有靶向其他蛋白质病(包括tau,即AD的另一主要神经病理性组分)的疗法。AD占折磨65岁以上的个体的痴呆的大部分,并且估计每年为AD和其他痴呆患者提供医疗保健、长期护理和临终关怀花费2260亿美元。这种广泛的经济和社会负担并未虑及许多家庭主要照顾者(包括配偶和其他家庭成员)的收入损失。
已显示增强自噬在治疗阿兹海默氏病中具有治疗潜能。自噬潮(包括自噬体与溶酶体的融合)是自噬的新型调节因子,这是因为其导致蛋白聚集体的清除和病理生理学衰退的逆转。因此,对自噬潮启动子和带有蛋白质病的自噬体的清除存在持续需求。
发明内容
在一些实施方案中,提供了本文公开的化合物(包括其药学上可接受的盐)。
在一些实施方案中,提供了包含本文公开的化合物或其药学上可接受的盐的药物组合物。在其他实施方案中,(例如)下文提供的实施例中还提供了制备所述化合物和药物组合物的方法。
在一些实施方案中,提供了治疗神经变性疾病的方法,其包括向有需要的个体施用有效量的本文公开的化合物或药物组合物。
在一些实施方案中,提供了增强自噬潮的方法。这种方法包括为细胞或蛋白聚集体提供有效量的本文公开的化合物或药物组合物。
在下面的详细描述和实施例中进一步公开了本发明的这些和其他方面。
图示简单说明
以下图示构成本说明书的一部分,并且包括以进一步说明本发明的某些方面。通过参考这些附图中的一个或多个结合本文提出的具体实施方案的详细描述,可以更好地理解本发明。
图1是显示小鼠脑中的WHYKD8的光电二极管阵列(PDA)光谱的图。
图2显示用WHYKD1(±BafA1)或WHYKD5处理6小时后原代皮质神经元中LC3-II水平的蛋白质印迹。
图3显示用WHYKD1(上图)或WHYKD3、WHYKD5、WHYKD8、WHYKD9或WHYKD12(下图)处理6小时后器官特征切片培养物中LC3-II、tau和p62水平的蛋白质印迹。
图4是显示WHYKD系列化合物(10μM)对磷脂酶D(PLD)的活化以及其在乙醇存在下将磷脂转化成磷脂酰乙醇的能力的条形图。C=对照,12=WHYKD12,15=WHYKD15,19=WHYKD19,5=WHYKD5,8=WHYKD8,Fipi=PLD活性的非竞争性抑制剂。
图5是显示WHYKD系列化合物(1μM)对磷脂酶D(PLD)的活化以及其在乙醇存在下将磷脂转化成磷脂酰乙醇的能力的条形图。
本发明的实施方式
尽管已知大自噬是一种必需的降解过程(其中自噬体介导细胞质组分被吞入和递送到溶酶体中),但不确定自噬体膜动力学下的脂质变化。发明人先前已经显示,主要与内体***相关的PLD1在营养饥饿时部分地重新定位到自噬体样结构的外膜(达尔·阿米(Dall'Armi),2010)。PLD1的定位以及饥饿诱导的PLD活性的增加被渥曼青霉素(wortmannin,一种磷脂酰肌醇3-激酶抑制剂)改变,表明PLD1可能作用于Vps34的下游。小鼠细胞中PLD的药理学抑制和PLD1的遗传消融减少了饥饿诱导的LC3阳性区室的扩张,这与PLD1在调控自噬中的作用一致。此外,抑制PLD导致器官特征脑切片中更高水平的tau和p62聚集体。这些体外和体内发现确立PLD1在自噬中起作用。
在一些实施方案中,提供具有式(II)的化合物:
其中Y1和Y2独立地选自由以下各项组成的组:CH和N;
其中X是选自由以下各项组成的组:H、卤基和芳基;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、羟基取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。在一个实施方案中,所述化合物是:
或其盐、对映异构体、外消旋物、混合物或其组合。在另一实施方案中,所述化合物是:
或其盐、对映异构体、外消旋物、混合物或其组合。在一些实施方案中,提供具有式(III)的化合物:
其中Y1是CH;
其中Y2是N;
其中X是卤基;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(IV)的化合物:
其中X是卤基;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(V)的化合物:
其中X是H;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(VI)的化合物:
其中X是H;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(VII)的化合物:
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(VIII)的化合物:
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(IX)的化合物:
其中Y3是CH或N;
其中R2是任选取代的(2-氨基乙基)芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(X)的化合物:
其中Y3是CH;
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(XI)的化合物:
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(XII)的化合物:
其中Y4是CH或N;
其中R3是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(XIII)的化合物:
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(XIV)的化合物:
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供具有式(XV)的化合物:
其中X是H或卤基;
其中Z1是O;
其中R4是选自由以下各项组成的组:H、任选取代的烷基、Et、CF3、任选取代的环烷基、任选取代的芳基、任选取代的杂芳基和
在一些实施方案中,所述化合物是选自由以下各项组成的组:
环烷基、芳基、杂芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
在一个实施方案中,所述化合物是
或其盐、对映异构体、外消旋物、混合物或其组合。
在一些实施方案中,提供了包含本文公开的化合物或其药学上可接受的盐的药物组合物。
在一些实施方案中,提供了治疗神经变性疾病的方法,其包括向有需要的个体施用有效量的本文公开的化合物或药物组合物。在一些实施方案中,神经变性疾病是蛋白质病。蛋白质病包括但不限于帕金森氏病(Parkinson’s disease)、阿兹海默氏病、肌萎缩侧索硬化(ALS)、亨廷顿氏病(Huntington’s disease)、慢性创伤性脑病(CTE)、额颞叶痴呆(FTD)、包涵体肌病(IBM)、佩吉特骨病(Paget's disease of bone,PDB)、大脑β-淀粉样蛋白血管病、朊病毒病、家族性痴呆、CADASIL、淀粉样变性、亚历山大病(Alexanderdisease)、腓骨肌萎缩症、II型糖尿病、肺泡蛋白沉积症、白内障、囊性纤维化和镰刀形细胞病。在这个实施方案的一些方面,蛋白质病是tau病。tau病包括但不限于阿兹海默氏病、帕金森氏病、亨廷顿氏病、进行性核上麻痹、慢性创伤性脑病(CTE)、额颞叶痴呆(FTD)、利替可-波帝格病(Lytico-Bodig disease)、亚急性硬化性全脑炎、神经节神经胶质瘤、神经节细胞瘤和嗜银颗粒疾病。在优选的实施方案中,神经变性疾病是阿兹海默氏病。
在一些实施方案中,提供了增强自噬潮的方法。这种方法包括为细胞或蛋白聚集体提供有效量的本文公开的化合物或药物组合物。
本公开中描述的实施方案可以以各种方式组合。针对一个实施方案描述的任何方面或特征可以并入本公开中提及的任何其他实施方案中。尽管已经显示、描述和指出了本发明原理的各种新颖特征应用于其特定实施方案,但应该理解,本领域技术人员可以做出各种省略和替代和改变而不脱离本公开的精神。本领域技术人员将认识到,本发明的原理可以在除了所描述的实施方案以外的其他实施方案中实施,所描述的实施方案是出于说明的目的而不是限制的目的而提供。
实施例
提供以下实施例以进一步说明本发明的某些方面。这些实施例只是说明性的,并不打算以任何方式限制本发明的范围。
实施例1
实例性合成方案
方案1显示下式化合物的合成:
例如,式(II)和式(III)化合物。
方案1
X=H,F,Cl,Br,l,CH3,CF3
Y=S,NH,N
Y1=CH,N
Y2=CH,N
Y3=CH,N
R1=H,烷基、环烷基、芳基、杂芳基
n=0,1
方案2显示1-氯-7-氟异喹啉的制备。
方案2
试剂和条件:a)氨基乙醛二甲基缩醛,苯,回流;
b)1.)ClCO2Et,-10℃,THF,2.)P(OCH3)3,3.)TiCl4,CH2Cl2,回流;c)H2O2,AcOH,60℃;d)1.)Ac2O,2.)NaOH;e)POCl3,回流
方案3显示下式化合物的合成:
例如,式(IV)、式(V)、式(VI)、式(VII)和式(VIII)化合物。
方案3
Y=CH,N
Y1=CH,N
Y2=CH,N
Y3=CH,N
Y4=CH,N
Y5=CH,N
Z=S,N,NH
R1=H,烷基、环烷基、芳基、杂芳基
n=0,1
方案4显示下式化合物的合成:
例如,式(XII)和式(XIII)化合物。
方案4
Y=CH,N
Y1=CH,N
Z=S,N,NH
R1=H,烷基、环烷基、芳基、杂芳基
n=0,1
方案5显示下式化合物的合成:
例如,式(IX)、式(X)和式(XI)化合物。
方案5
X=O,S
Y=CH,N
Y1=CH,N
Z=S,N,NH
R1=H,烷基、环烷基、芳基、杂芳基
n=0,1
方案6显示下式化合物的合成:
例如,式(XIV)化合物。
方案6
Y=CH,N
Y1=CH,N
Z=S,N,NH
R1=H,烷基、环烷基、芳基、杂芳基
n=0,1
实施例2
自噬潮和磷脂酶D的活化剂
基于分子量(MW)和分配系数(log P),根据李平斯基的CNS渗透率原则(Lipinski’s Rule for CNS penetrance):MW≤400,log P≤5,合成WHYKD系列化合物以获得最佳脑渗透率。
根据下式的活化剂:
是根据上述方案合成。计算分子量和log P。结果显示于下表1中。
表1
根据下式的活化剂:
是根据上述方案合成。计算分子量和log P。结果显示于下表2中。
表2
根据下式的活化剂:
是根据上述方案合成。计算分子量和log P。结果显示于下表3中。
表3
根据下式的活化剂:
是根据上述方案合成。计算分子量和log P。结果显示于下表4中。
表4
实施例3
衍生物的设计
多个系列的衍生物是基于以下先导化合物来合成:
除了log P之外,还计算了拓扑极性表面积(tPSA)、CLogP(通过基团贡献法计算的log P)和LogS(溶解度)。结果显示于下表中。
表5:对核和侧链做出的修改(系列1)
表6:对核和侧链做出的修改(系列2)
表7:对核和侧链做出的修改(系列3)
表8:对核和侧链做出的修改(系列4)
表9:对核和侧链做出的修改(系列5)
表10:对核和侧链做出的修改(系列6)
表11:对核和侧链做出的修改(系列7)
表12:对核和侧链做出的修改(系列8)
表13:对核和侧链做出的修改(系列9)
表14:对核和侧链做出的修改(系列10)
表15:喹唑啉酮(系列11)
实施例4
WHYKD化合物的检测和结果
使用光电二极管阵列(PDA)检测小鼠脑中的WHYKD8(图1)。利用基于时间的离散峰(左)以及利用可测量的曲线下面积(AUC)(插图)容易地检测到样品。
在用WHYKD1、WHYKD5或WHYKD1+BafA1处理6小时后,测量原代皮质神经元中的LC3-II水平(图2)。LC3-II的存在指示自噬。
在用WHYKD1处理6小时后,然后测量器官特征切片培养物中的LC3-II水平(图3,顶部小图)。WHYKD系列中的其他化合物产生了类似的结果(图3,底部小图)。RFP是tau蛋白上的标签,并且也可以被探测。
这些实验显示,WHYKD系列化合物可以诱导自噬并减少聚集形式的τ以及其聚集体替代物p62。
PLD活化在乙醇存在下将磷脂转化成磷脂酰乙醇。测量所述转化以显示WHYKD系列化合物以10μM浓度(图4)和1μM(图5)活化PLD。FIPI是PLD活性的非竞争性抑制剂,并用作阴性对照。
上文引用的所有专利、专利申请和出版物通过引用整体并入本文,如同在本文中全部引用一样。
由此描述了本发明,显而易见的是其可以以多种方式变化。不认为这些变化背离本发明的精神和范围,并且所有所述修改均打算包括在下面的权利要求的范围内。
Claims (37)
1.一种具有式(II)的化合物,
其中Y1和Y2独立地选自由以下各项组成的组:CH和N;
其中X是选自由以下各项组成的组:H、卤基和芳基;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、羟基取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
2.如权利要求1所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
3.如权利要求1所述的化合物,其中所述化合物是:
或其盐、对映异构体、外消旋物、混合物或其组合。
4.如权利要求1所述的化合物,其中所述化合物是:
或其盐、对映异构体、外消旋物、混合物或其组合。
5.一种具有式(III)的化合物,
其中Y1是CH;
其中Y2是N;
其中X是卤基;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
6.如权利要求5所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
7.一种具有式(IV)的化合物,
其中X是卤基;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
8.如权利要求7所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
9.一种具有式(V)的化合物,
其中X是H;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
10.如权利要求9所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
11.一种具有式(VI)的化合物,
其中X是H;
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
12.如权利要求11所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
13.一种具有式(VII)的化合物,
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
14.如权利要求13所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
15.一种具有式(VIII)的化合物,
其中R1是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
16.如权利要求15所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
17.一种具有式(IX)的化合物,
其中Y3是CH或N;
其中R2是任选取代的(2-氨基乙基)芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
18.如权利要求17所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
19.一种具有式(X)的化合物,
其中Y3是CH;
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
20.如权利要求19所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
21.一种具有式(XI)的化合物,
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
22.如权利要求21所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
23.一种具有式(XII)的化合物,
其中Y4是CH或N;
其中R3是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
24.如权利要求23所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
25.一种具有式(XIII)的化合物,
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
26.如权利要求25所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
27.一种具有式(XIV)的化合物,
其中R2是选自由以下各项组成的组:任选取代的硫代杂芳基、任选取代的(2-氨基乙基)芳基、卤基、任选取代的硫代环烷基,其中所述环烷基的1到3个碳原子任选地由选自由O、S和N组成的组的杂原子置换;和硫代芳基,
或其盐、对映异构体、外消旋物、混合物或其组合。
28.如权利要求27所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
29.一种具有式(XV)的化合物,
其中X是H或卤基;
其中Z1是O;
其中R4是选自由以下各项组成的组:H、任选取代的烷基、Et、CF3、任选取代的环烷基、任选取代的芳基、任选取代的杂芳基和
30.如权利要求29所述的化合物,其中所述化合物是选自由以下各项组成的组:
或其盐、对映异构体、外消旋物、混合物或其组合。
31.如权利要求29所述的化合物,其中所述化合物是:
或其盐、对映异构体、外消旋物、混合物或其组合。
32.一种药物组合物,其包含如权利要求1至31中任一项所述的化合物或其药学上可接受的盐。
33.一种治疗神经变性疾病的方法,其包括向有需要的个体施用有效量的如权利要求1至31中任一项所述的化合物或如权利要求32所述的药物组合物。
34.如权利要求33所述的方法,其中所述神经变性疾病是蛋白质病。
35.如权利要求34所述的方法,其中所述蛋白质病是tau病。
36.如权利要求33所述的方法,其中所述神经变性疾病是阿兹海默氏病。
37.一种增强自噬潮的方法,其包括为细胞或蛋白聚集体提供有效量的如权利要求1至31中任一项所述的化合物或如权利要求32所述的药物组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562237342P | 2015-10-05 | 2015-10-05 | |
US62/237,342 | 2015-10-05 | ||
PCT/US2016/055561 WO2017062500A2 (en) | 2015-10-05 | 2016-10-05 | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108473435A true CN108473435A (zh) | 2018-08-31 |
Family
ID=58488491
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680062131.XA Pending CN108473435A (zh) | 2015-10-05 | 2016-10-05 | 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 |
CN201780064731.4A Pending CN110023289A (zh) | 2015-10-05 | 2017-10-03 | 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780064731.4A Pending CN110023289A (zh) | 2015-10-05 | 2017-10-03 | 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 |
Country Status (12)
Country | Link |
---|---|
US (6) | US20190112317A1 (zh) |
EP (2) | EP3359526A4 (zh) |
JP (3) | JP6740354B2 (zh) |
KR (2) | KR20180086187A (zh) |
CN (2) | CN108473435A (zh) |
AU (2) | AU2016333987A1 (zh) |
BR (2) | BR112018006873A2 (zh) |
CA (2) | CA3000988A1 (zh) |
IL (2) | IL258498A (zh) |
MX (2) | MX2018004109A (zh) |
WO (2) | WO2017062500A2 (zh) |
ZA (2) | ZA201802294B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018006873A2 (pt) * | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
WO2020109039A1 (en) | 2018-11-28 | 2020-06-04 | Basf Se | Pesticidal compounds |
CN113454076A (zh) * | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用于激活造血干细胞和祖细胞的芳香族化合物 |
TW202228676A (zh) | 2020-09-17 | 2022-08-01 | 日商昭和電工股份有限公司 | 自噬活化劑 |
TW202228715A (zh) | 2020-09-17 | 2022-08-01 | 日商昭和電工股份有限公司 | 自噬活化劑 |
EP4215199A1 (en) | 2020-09-17 | 2023-07-26 | Resonac Corporation | Autophagy activator |
EP4215200A1 (en) | 2020-09-17 | 2023-07-26 | Resonac Corporation | Autophagy activator |
CN112209888B (zh) * | 2020-10-14 | 2024-02-02 | 河南中医药大学 | 一种4-芳巯基喹唑啉类化合物、制备方法和医药用途 |
WO2023081860A1 (en) * | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Triazine amino derivatives for treating sca3 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115736A (zh) * | 2005-03-14 | 2008-01-30 | 神经研究公司 | 钾通道调节剂和它们的医药用途 |
CN101553490A (zh) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | 用作蛋白激酶调节剂的二环***类化合物 |
US20120129877A1 (en) * | 2009-05-20 | 2012-05-24 | Consejo Superior De Investigaciones Cientificas | Use of quinazoline derivatives for neurodegenerative diseases |
CN103298460A (zh) * | 2010-12-14 | 2013-09-11 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
CN104193728A (zh) * | 2014-08-26 | 2014-12-10 | 北京大学深圳研究生院 | 流感病毒抑制剂及其应用 |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272824A (en) | 1962-12-06 | 1966-09-13 | Norwich Pharma Co | 4-amino-6, 7-di(lower) alkoxyquinolines |
US3266990A (en) | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
US3936461A (en) | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
US4114939A (en) | 1976-09-13 | 1978-09-19 | Conco Inc. | Vacuum pickup head |
IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
IL89027A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them |
IL89028A0 (en) | 1988-01-29 | 1989-08-15 | Lilly Co Eli | Quinoline,quinazoline and cinnoline derivatives |
WO1990005523A2 (en) | 1988-11-15 | 1990-05-31 | The Upjohn Company | Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase |
US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
JPH0772176B2 (ja) | 1991-04-03 | 1995-08-02 | コリア リサーチ インスティチュート オブ ケミカル テクノロジイ | 2―キノリノン誘導体 |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
JPH05213884A (ja) | 1991-06-14 | 1993-08-24 | Upjohn Co:The | 新規な4−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤 |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
AU4790893A (en) | 1992-08-19 | 1994-03-15 | Dowelanco | Pyridylethoxy-, pyridylethylamino-, and pyridylpropyl-derivatives of quinoline and quinazoline as insecticides and fungicides |
US5326766A (en) * | 1992-08-19 | 1994-07-05 | Dreikorn Barry A | 4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and analogues thereof |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
EP0832073B1 (en) | 1995-06-07 | 2002-01-16 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
JP4009681B2 (ja) | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 |
HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
EP0929526B1 (en) | 1996-09-25 | 2005-07-27 | AstraZeneca AB | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
AU1631699A (en) | 1997-12-18 | 1999-07-05 | E.I. Du Pont De Nemours And Company | Cyclohexylamine arthropodicides and fungicides |
DE69917201T2 (de) * | 1998-07-22 | 2005-05-04 | Daiichi Suntory Pharma Co., Ltd. | Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
WO2000021955A1 (en) | 1998-10-08 | 2000-04-20 | Astrazeneca Ab | Quinazoline derivatives |
US6797823B1 (en) | 1999-01-22 | 2004-09-28 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives |
PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910580D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
KR20020032608A (ko) | 1999-09-21 | 2002-05-03 | 다비드 에 질레스 | 퀴나졸린 화합물 및 이를 함유하는 제약 조성물 |
DE60043349D1 (de) | 1999-09-21 | 2009-12-31 | Astrazeneca Ab | Chinazolin-derivate und ihre verwendung als arzneimittel |
GB9930061D0 (en) | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Quinolone compounds for use in treating viral infections |
AU2223201A (en) | 1999-12-24 | 2001-07-09 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
ES2267748T3 (es) | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | Compuestos de quinazolina. |
EP1299381B1 (en) | 2000-06-28 | 2008-05-07 | AstraZeneca AB | Substituted quinazoline derivatives and their use as inhibitors |
DE10042064A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
ES2312557T3 (es) | 2001-04-19 | 2009-03-01 | Astrazeneca Ab | Derivados de quinazolina. |
NZ529046A (en) | 2001-04-27 | 2005-10-28 | Kirin Brewery | Quinoline derivative having azolyl group and quinazoline derivative |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
DE60233736D1 (de) | 2001-06-22 | 2009-10-29 | Kirin Pharma K K | Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung |
DE60215178T2 (de) | 2001-07-16 | 2007-08-23 | Astrazeneca Ab | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase |
WO2003033472A1 (fr) | 2001-10-17 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes |
US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
AU2002365665A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours |
WO2003047584A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
AU2002347336A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
AU2002365664A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives as antitumour agents |
WO2003047585A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours |
AU2002361846A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
US7268230B2 (en) | 2002-02-01 | 2007-09-11 | Astrazeneca Ab | Quinazoline compounds |
AU2003235838A1 (en) | 2002-05-01 | 2003-11-17 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ATE429230T1 (de) | 2002-07-09 | 2009-05-15 | Astrazeneca Ab | Chinazoline derivative und ihre anwendung in der krebsbehandlung |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
TW200420542A (en) | 2002-08-23 | 2004-10-16 | Kirin Brewery | A compound having TGF β inhibition activity and a medicinal composition containing the same |
WO2004039782A1 (ja) | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
BR0315756A (pt) | 2002-11-04 | 2005-09-06 | Astrazeneca Ab | Derivado de quinazolina ou um seu sal farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de um seu sal farmaceuticamente aceitável, e, método para produzir um efeito anti-invasivo pela detenção e/ou pelo tratamento de doença de tumor sólido em um animal de sangue quente necessitando de tal tratamento |
JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
WO2004111014A1 (en) * | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
CN1838950A (zh) * | 2003-06-23 | 2006-09-27 | 神经化学(国际)有限公司 | 治疗蛋白质聚集疾病的方法 |
US20050026805A1 (en) | 2003-07-14 | 2005-02-03 | Ici Americas, Inc. | Solvated nonionic surfactants and fatty acids |
GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
MXPA06007017A (es) | 2003-12-18 | 2006-08-31 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidina como agentes antiproliferativos. |
NZ547795A (en) | 2003-12-18 | 2009-07-31 | Janssen Pharmaceutica Nv | 3-Cyano-quinoline derivatives with antiproliferative activity |
JP4503022B2 (ja) | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
US7432377B2 (en) | 2004-01-16 | 2008-10-07 | Wyeth | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof |
KR100910333B1 (ko) | 2005-02-23 | 2009-07-31 | 시오노기세이야쿠가부시키가이샤 | 타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체 |
MX2007010991A (es) * | 2005-03-14 | 2007-11-07 | Neurosearch As | Agentes que modulan el canal de potasio y su uso medico. |
EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
WO2006121767A2 (en) | 2005-05-06 | 2006-11-16 | Apath, Llc | 4-aminoquinoline compounds for treating virus-related conditions |
KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용 |
WO2007055513A1 (en) | 2005-11-08 | 2007-05-18 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof |
EP1948179A1 (en) | 2005-11-11 | 2008-07-30 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
JP2009521480A (ja) | 2005-12-21 | 2009-06-04 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
EP1981863B1 (en) | 2006-01-26 | 2012-10-10 | Boehringer Ingelheim International GmbH | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
BRPI0713253A2 (pt) | 2006-07-07 | 2012-10-30 | Steven P Govek | método de inibição de pde4, método de tratamento de um doença mediada por pde4, composto e composição farmacêutica |
US8673929B2 (en) | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
WO2008024423A2 (en) | 2006-08-23 | 2008-02-28 | Xtl Biopharmaceuticals Ltd. | 4-thio substituted quinoline and naphthyridine compounds |
EP2114898A2 (en) | 2007-02-16 | 2009-11-11 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
DE102007032739A1 (de) | 2007-07-13 | 2009-01-15 | Merck Patent Gmbh | Chinazolinamidderivate |
MX2009014235A (es) | 2007-08-22 | 2010-04-27 | Abbott Gmbh & Co Kg | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. |
US8143276B2 (en) | 2007-08-22 | 2012-03-27 | Xtl Biopharmaceuticals Ltd. | 4-thio substituted quinoline and naphthyridine compounds |
WO2009090661A1 (en) | 2008-01-18 | 2009-07-23 | Natco Pharma Limited | 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders |
US20110045100A1 (en) | 2008-03-05 | 2011-02-24 | Georgetown University | Antimalarial Quinolines and Methods of Use Thereof |
KR101601997B1 (ko) | 2008-03-17 | 2016-03-17 | 암비트 바이오사이언시즈 코포레이션 | Raf 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법 |
US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
WO2010002779A2 (en) | 2008-07-03 | 2010-01-07 | Merck Serono S.A. | Naphthyridininones as aurora kinase inhibitors |
AP2848A (en) | 2008-08-14 | 2014-02-28 | Univ Cape Town | Quinoline compounds containing a dibemethin group |
WO2010025451A2 (en) | 2008-08-29 | 2010-03-04 | Dow Agrosciences Llc | 5,8-difluoro-4-(2-(4-(heteroaryloxy)-phenyl)ethylamino)quinazolines and their use as agrochemicals |
IT1393351B1 (it) | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
JP2012520891A (ja) | 2009-03-19 | 2012-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホニルキノリンの製造方法 |
RU2011142597A (ru) | 2009-03-21 | 2013-04-27 | Саншайн Лейк Фарма Ко., Лтд. | Производные сложных эфиров аминокислот, их соли и способы применения |
UY32742A (es) | 2009-06-25 | 2010-12-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
PH12012500097A1 (en) * | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
WO2011014039A1 (en) * | 2009-07-31 | 2011-02-03 | Rohm And Haas Electronic Materials Korea Ltd. | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
CA2848577C (en) | 2010-01-04 | 2016-02-16 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and agricultural fungicide |
US8575203B2 (en) | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
WO2011143444A2 (en) * | 2010-05-14 | 2011-11-17 | President And Fellows Of Harvard College | Diphenylbutypiperidine autophagy inducers |
JP2013533883A (ja) | 2010-06-30 | 2013-08-29 | アムジエン・インコーポレーテツド | PI3Kδ阻害剤としての含窒素複素環化合物 |
US20120015942A1 (en) * | 2010-07-19 | 2012-01-19 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
UY33549A (es) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
WO2012044993A1 (en) * | 2010-09-30 | 2012-04-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders |
WO2012090179A2 (en) * | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
EA023998B1 (ru) | 2011-03-04 | 2016-08-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Аминохинолины в качестве ингибиторов киназ |
US8664230B2 (en) | 2011-03-17 | 2014-03-04 | The Asan Foundation | Pyridopyrimidine derivatives and use thereof |
ITMI20110480A1 (it) | 2011-03-25 | 2012-09-26 | F I S Fabbrica Italiana Sint P A | Procedimento per la preparazione di lapatinib e suoi sali |
US8969363B2 (en) * | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PL2780338T3 (pl) | 2011-11-14 | 2017-04-28 | Ignyta, Inc. | Pochodne uracylu jako inhibitory kinaz AXL i c-MET |
CN102643268B (zh) | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
WO2013140148A1 (en) | 2012-03-19 | 2013-09-26 | Imperial Innovations Limited | Quinazoline compounds and their use in therapy |
WO2013143057A1 (zh) | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及用途 |
AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
US9024023B2 (en) | 2013-01-14 | 2015-05-05 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. | Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
BR112015023222A2 (pt) | 2013-03-15 | 2017-07-18 | Rexahn Pharmaceuticals Inc | compostos tetraidroisoquinolin-2-il-(quinazolin-4-il)metanona como inibidores do crescimento de células cancerosas |
CN103232401B (zh) * | 2013-04-12 | 2015-11-04 | 浙江工业大学 | 一种4-芳硫基喹唑啉类化合物的合成方法 |
US20160101106A1 (en) | 2013-05-07 | 2016-04-14 | Inhibikase Therapeutics, Inc. | Methods for treating hcv infection |
ES2668721T3 (es) | 2013-05-13 | 2018-05-21 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Derivado de ácido de cicloalquilo, método de preparación y aplicación farmacéutica del mismo |
CN105916506B (zh) | 2013-11-20 | 2020-01-07 | 圣诺康生命科学公司 | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
GB201321126D0 (en) * | 2013-11-29 | 2014-01-15 | Velgene Biotechnology | Autophagy stimulants |
GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
EP3091984B1 (en) * | 2014-01-09 | 2020-04-22 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Substituted benzoxazine and related compounds |
BR112016021730B1 (pt) | 2014-03-24 | 2022-09-06 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Derivados de quinolina como inibidores de smo |
FR3019819B1 (fr) | 2014-04-09 | 2018-03-23 | Centre National De La Recherche Scientifique (Cnrs) | Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline |
MX2016013668A (es) | 2014-04-22 | 2017-01-20 | Nimbus Iris Inc | Inhibidores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
BR112018006873A2 (pt) * | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
US9853396B1 (en) | 2016-12-05 | 2017-12-26 | Delphi Technologies, Inc. | Electrical plug having a flexible terminal retention feature |
-
2016
- 2016-10-05 BR BR112018006873-0A patent/BR112018006873A2/pt not_active IP Right Cessation
- 2016-10-05 JP JP2018536715A patent/JP6740354B2/ja active Active
- 2016-10-05 US US15/765,801 patent/US20190112317A1/en not_active Abandoned
- 2016-10-05 CA CA3000988A patent/CA3000988A1/en not_active Abandoned
- 2016-10-05 AU AU2016333987A patent/AU2016333987A1/en not_active Abandoned
- 2016-10-05 CN CN201680062131.XA patent/CN108473435A/zh active Pending
- 2016-10-05 KR KR1020187012344A patent/KR20180086187A/ko not_active Application Discontinuation
- 2016-10-05 MX MX2018004109A patent/MX2018004109A/es unknown
- 2016-10-05 WO PCT/US2016/055561 patent/WO2017062500A2/en active Application Filing
- 2016-10-05 EP EP16854245.4A patent/EP3359526A4/en not_active Withdrawn
-
2017
- 2017-04-05 US US15/480,220 patent/US10487091B2/en active Active
- 2017-10-03 BR BR112019006887A patent/BR112019006887A2/pt not_active Application Discontinuation
- 2017-10-03 KR KR1020197012934A patent/KR20190058620A/ko unknown
- 2017-10-03 EP EP17859036.0A patent/EP3523281A4/en not_active Withdrawn
- 2017-10-03 WO PCT/US2017/054969 patent/WO2018067589A1/en unknown
- 2017-10-03 CA CA3037260A patent/CA3037260A1/en not_active Abandoned
- 2017-10-03 JP JP2019518267A patent/JP2019529514A/ja active Pending
- 2017-10-03 AU AU2017338769A patent/AU2017338769A1/en not_active Abandoned
- 2017-10-03 MX MX2019003805A patent/MX2019003805A/es unknown
- 2017-10-03 CN CN201780064731.4A patent/CN110023289A/zh active Pending
-
2018
- 2018-04-04 IL IL258498A patent/IL258498A/en unknown
- 2018-04-09 ZA ZA2018/02294A patent/ZA201802294B/en unknown
- 2018-07-05 US US16/027,951 patent/US11230558B2/en active Active
- 2018-07-05 US US16/027,930 patent/US11008341B2/en active Active
- 2018-07-05 US US16/027,990 patent/US10865214B2/en active Active
-
2019
- 2019-03-19 ZA ZA2019/01694A patent/ZA201901694B/en unknown
- 2019-04-01 IL IL265750A patent/IL265750B/en unknown
-
2020
- 2020-03-13 US US16/818,388 patent/US11261199B2/en active Active
- 2020-06-12 JP JP2020102147A patent/JP2020147597A/ja not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115736A (zh) * | 2005-03-14 | 2008-01-30 | 神经研究公司 | 钾通道调节剂和它们的医药用途 |
CN101553490A (zh) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | 用作蛋白激酶调节剂的二环***类化合物 |
US20120129877A1 (en) * | 2009-05-20 | 2012-05-24 | Consejo Superior De Investigaciones Cientificas | Use of quinazoline derivatives for neurodegenerative diseases |
CN103298460A (zh) * | 2010-12-14 | 2013-09-11 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
CN104906103A (zh) * | 2010-12-14 | 2015-09-16 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
CN104193728A (zh) * | 2014-08-26 | 2014-12-10 | 北京大学深圳研究生院 | 流感病毒抑制剂及其应用 |
Non-Patent Citations (15)
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108473435A (zh) | 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 | |
Fouladi et al. | Phase I study of everolimus in pediatric patients with refractory solid tumors | |
Dar et al. | Chemical genetic discovery of targets and anti-targets for cancer polypharmacology | |
Eskens et al. | Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors | |
AbouAlaiwi et al. | Endothelial cells from humans and mice with polycystic kidney disease are characterized by polyploidy and chromosome segregation defects through survivin down-regulation | |
Bai et al. | Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts | |
CN100553631C (zh) | 4-氟-n-(1,2-二氢化茚-2-基)苯甲酰胺的制药用途 | |
Lin et al. | Digoxin suppresses tumor malignancy through inhibiting multiple Src-related signaling pathways in non-small cell lung cancer | |
Fan et al. | Pharmacological inhibition of focal adhesion kinase attenuates cardiac fibrosis in mice cardiac fibroblast and post-myocardial-infarction models | |
Wang et al. | Puerarin attenuates osteoarthritis via upregulating AMP-activated protein kinase/proliferator-activated receptor-γ coactivator-1 signaling pathway in osteoarthritis rats | |
Zhao et al. | Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo | |
Kiyota et al. | Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27KIP1 and p15INK4B and induces G1 arrest in oral squamous carcinoma cell lines | |
AU2014312919A1 (en) | Pharmaceutical composition having pyrimidine compound as active ingredient | |
ES2869463T3 (es) | Composición para la prevención o tratamiento de la calcificación de válvulas que contiene un inhibidor de DPP-4 | |
CN104363913A (zh) | Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 | |
Weiss et al. | Differential diagnosis of Schnyder corneal dystrophy | |
Han et al. | Hydrogen sulfide inhibits abnormal proliferation of lymphocytes via AKT/GSK3β signal pathway in systemic lupus erythematosus patients | |
CN106822128A (zh) | 酪氨酸激酶抑制剂dcc‑2036的新应用 | |
Kawakami et al. | Synthesis and evaluation of novel rhodacyanine dyes that exhibit antitumor activity | |
Zhang et al. | Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa | |
TWI445696B (zh) | 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的dna修復毒性 | |
Moon et al. | Global Deletion of Pannexin 3 Resulting in Accelerated Development of Aging‐Induced Osteoarthritis in Mice | |
Li et al. | mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers | |
Fan et al. | Rosiglitazone attenuates activation of human Tenon’s fibroblasts induced by transforming growth factor-β1 | |
CN109106715B (zh) | 8-羟基喹啉类药物或其盐在制备用于治疗与brd4相关的疾病的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180831 |